<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="169">
  <stage>Registered</stage>
  <submitdate>10/08/2005</submitdate>
  <approvaldate>15/08/2005</approvaldate>
  <actrnumber>ACTRN12605000146695</actrnumber>
  <trial_identification>
    <studytitle>Redback Spider AntiVenom Evaluation (RAVE) Study</studytitle>
    <scientifictitle>Randomised controlled trial of antivenom for the treatment of pain in redback spider bite; intravenous versus intramuscular antivenom.</scientifictitle>
    <utrn />
    <trialacronym>RAVE</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Redback spider envenoming</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study compares 2 methods of administration of the same antivenom. The "active" group is intravenous antivenom (500U redback spider antivenom [CSL Ltd] diluted in 200 mL normal saline and given over 20 minutes; patient also receives a dummy intramuscual injection of 0.5mL normal saline). </interventions>
    <comparator>"Current standard of care" is intramuscular antivenom (500 U redback spider antivenom [CSL Ltd] by intramuscular injection; patient also received a dummy 0.5mL normal saline diluted in 200mL normal saline over 20 minutes.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinically important reduction in pain </outcome>
      <timepoint>2 hours after antivenom treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>A clinically significant reduction in pain on the VAS on discharge.</outcome>
      <timepoint>Discharge time</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction in systemic symptoms and signs during ED admission.</outcome>
      <timepoint>By discharge time</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Requirement for a third dose or further doses of antivenom.</outcome>
      <timepoint>By discharge time</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinically significant change in VAS (or verbal analogue score where the VAS was not obtained).</outcome>
      <timepoint>At 24 hours.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of analgesics in the emergency department after commencing antivenom treatment.</outcome>
      <timepoint>By discharge time</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Use of analgesics after discharge.</outcome>
      <timepoint>For up to 7 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>(1) definite redback spider-bite and the spider is identified by the patient or clinician at the time of the bite; OR (2) clinical syndrome that is consistent with typical redback envenoming; AND the treating clinician would normally treat the patient with antivenom, namely: - moderate envenoming = severe local pain without systemic envenoming- severe envenoming = severe local pain and systemic features.</inclusivecriteria>
    <inclusiveminage>8</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients who have received antivenom for this envenoming prior to enrolment2. Children aged &lt;8 years 3. Bite occurring &gt;24 hours ago</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Only the pharmacist knows the allocation. The treatment pack contains 2 ampoules, one labelled "IM" and one labelled "IV" - patient gets both by the allocated routes and onlt the pharmacy knows which is antivenom</concealment>
    <sequence>Computer generated; blocking.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Comparison of intramuscular and intravenous antivenom, placebo used so that all patients get an IV and IM injection</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2003</anticipatedstartdate>
    <actualstartdate>19/01/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/03/2007</actualenddate>
    <samplesize>400</samplesize>
    <actualsamplesize>130</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/03/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,WA</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Geoff Isbister</primarysponsorname>
    <primarysponsoraddress>Dept of Clinical Toxicology 
Calvary Mater Newcastle
Edith St Waratah NSW 2298</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study has been published 
A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study.

Isbister GK, Brown SG, Miller M, Tankel A, Macdonald E, Stokes B, Ellis R, Nagree Y, Wilkes GJ, James R, Short A, Holdgate A.

QJM. 2008 Jul;101(7):557-65.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Area Health Service-Newcastle Mater Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hunter New England Area Health Service-John Hunter Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hunter New England Area Health Service-Maitland Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hunter New England Area Health Service-Tamworth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hunter New England Area Health Service-Belmont Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>2/12/2002</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>30/10/2002</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Coffs Harbour Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Fremantle Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Rockingham Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Armadale Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bunbury Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Geoff Isbister</name>
      <address>Department of Clinical Toxicology and Pharmacology
Newcastle Mater Hospital
Edith St
Waratah NSW 2298</address>
      <phone>+61 2 49211211</phone>
      <fax />
      <email>geoff.isbister@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Geoff Isbister</name>
      <address>Department of Clinical Toxicology and Pharmacology
Newcastle Mater Hospital
Edith St
Waratah NSW 2298</address>
      <phone>+61 2 49211211</phone>
      <fax />
      <email>geoff.isbister@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Geoffrey Isbister</name>
      <address>Calvary Mater Newcastle
Waratah NSW 2298</address>
      <phone>o438466471</phone>
      <fax />
      <email>geoff.isbister@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>